Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.57 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.57 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naptalam SCHEMBL8537412 | 0.85 | HSD17B10 (0.74) | HSD17B10RAB9ANPC1CYP2C9CYP1A2 | |
| Naptalam SCHEMBL29610802 | 0.85 | HSD17B10 (0.74) | HSD17B10RAB9ANPC1CYP2C9CYP1A2 | |
| Naptalam SCHEMBL54940 | 0.85 | HSD17B10 (0.74) | HSD17B10RAB9ANPC1CYP2C9CYP1A2 | |
| Naptalam SCHEMBL29469565 | 0.85 | HSD17B10 (0.74) | HSD17B10RAB9ANPC1CYP2C9CYP1A2 | |
| Naptalam SCHEMBL984498 | 0.84 | HSD17B10 (0.72) | HSD17B10RAB9ANPC1CYP2C9CYP1A2 | |
| SCHEMBL27561288 | 0.82 | RAB9A (0.79) | HSD17B10RAB9ANPC1CYP2C9CYP1A2 | |
| SCHEMBL3660790 | 0.82 | HSD17B10 (0.70) | HSD17B10RAB9ANPC1CYP2C9CYP1A2 | |
| SCHEMBL3659854 | 0.82 | HSD17B10 (0.70) | HSD17B10RAB9ANPC1CYP2C9CYP1A2 | |
| SCHEMBL3659724 | 0.82 | RAB9A (0.84) | HSD17B10RAB9ANPC1CYP2C9CYP1A2 | |
| SCHEMBL7084829 | 0.81 | HSD17B10 (0.67) | HSD17B10RAB9ANPC1CYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080139-A1 | Naaladase inhibitors for treating huntington's disease | GUILFORD PHARMACEUTICALS INC. | 2005-04-14 | — | — | US | claimed |
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | GUILFORD PHARMACEUTICALS INC. | 2004-09-23 | — | — | US | claimed |
| WO-2004078180-A2 | NAALADASE INHIBITORS FOR TREATING OPIOID TOLERANCE | GUILFORD PHARMACEUTICALS INC. (US) | 2004-09-16 | — | — | WO | claimed |
| WO-2003057154-A2 | NAALADASE INHIBITORS FOR TREATING HUNTINGTON'S DISEASE | GUILDFORD PHARMACEUTICALS INC. (US) | 2003-07-17 | — | — | WO | claimed |
| EP-1292601-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2003-03-19 | — | — | EP | claimed |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | EISAI INC. | 2003-02-20 | — | — | US | claimed |
| US-6452044-B2 | NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-09-17 | — | — | US | claimed |
| US-20020019430-A1 | Nervous system and psychological disorders | EISAI INC. | 2002-02-14 | — | — | US | claimed |
| US-20020013295-A1 | Naaladase inhibitors for treating amyotrophic lateral sclerosis | GUILFORD PHARMACEUTICALS INC., A DELAWARE CORPORATION | 2002-01-31 | — | — | US | claimed |
| WO-2001092274-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | claimed |
| WO-2001091738-A2 | NAALADASE INHIBITORS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | claimed |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-12-18 | — | — | US | disclosed |
| US-7220780-B2 | Naaladase inhibitors for treating retinal disorders and glaucoma | GUILFORD PHARMACEUTICALS INC. (US) | 2007-05-22 | — | — | US | disclosed |
| WO-2006093991-A1 | COMPOUNDS WHICH BIND PSMA AND USES THEREOF | THE CLEVELAND CLINIC FOUNDATION (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20050171065-A1 | NAALADas, N-Acetylated-Alpha-Linked-Acidic-Dipeptidase inhibitors; 5-phosphonomethyl-1,3-benzenedicarboxylic Acid; glutamate abnormalities, anticancer, antidiabetic agent, angiogenesis inhibitor, neuropathy, pain, compulsive disorders, prostate diseases, glaucoma | GUILFORD PHARMACEUTICALS INC. | 2005-08-04 | — | — | US | disclosed |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | EISAI INC. | 2003-02-20 | — | — | US | disclosed |
| US-6452044-B2 | NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-09-17 | — | — | US | disclosed |
| US-20020013295-A1 | Naaladase inhibitors for treating amyotrophic lateral sclerosis | GUILFORD PHARMACEUTICALS INC., A DELAWARE CORPORATION | 2002-01-31 | — | — | US | disclosed |
| WO-2001092274-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001091738-A2 | NAALADASE INHIBITORS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013295-A1 | Naaladase inhibitors for treating amyotrophic lateral sclerosis | SMN1; SMN2, GAA, NAALAD2 | HSD17B10 1572/4885RAB9A 1588/4885NPC1 162/4885 |
| US-20050080139-A1 | Naaladase inhibitors for treating huntington's disease | HTT, GAA, ADA | HSD17B10 418/4885RAB9A 2315/4885NPC1 221/4885 |
| US-20080311037-A1 | Compounds which bind PSMA and uses thereof | FOLH1, PSMA1, BPHL | HSD17B10 2227/4885RAB9A 2236/4885NPC1 358/4885 |
| US-20050171065-A1 | NAALADas, N-Acetylated-Alpha-Linked-Acidic-Dipeptidase inhibitors; 5-phosphonomethyl-1,3-benzenedicarboxylic Acid; glutamate abnormalities, anticancer, antidiabetic agent, angiogenesis inhibitor, neuropathy, pain, compulsive disorders, prostate diseases, glaucoma | NAALAD2, GLUL, DNPEP | HSD17B10 1053/4885RAB9A 4076/4885NPC1 2472/4885 |
| US-20020019430-A1 | Nervous system and psychological disorders | GLUL, DDC, DNPEP | HSD17B10 965/4885RAB9A 3786/4885NPC1 3592/4885 |
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | OPRD1, OPRK1, OPRM1 | HSD17B10 645/4885RAB9A 2424/4885NPC1 613/4885 |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | ALDH1A2, GAA, PDE6A | HSD17B10 622/4885RAB9A 573/4885NPC1 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.